Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...

Descripción completa

Detalles Bibliográficos
Autores principales: Affronti, Mary Lou, Jackman, Jennifer Gamboa, McSherry, Frances, Herndon, James E., Massey, Elwood C., Lipp, Eric, Desjardins, Annick, Friedman, Henry S., Vlahovic, Gordana, Vredenburgh, James, Peters, Katherine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://www.ncbi.nlm.nih.gov/pubmed/29666296
http://dx.doi.org/10.1634/theoncologist.2018-0149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://www.ncbi.nlm.nih.gov/pubmed/29666296
http://dx.doi.org/10.1634/theoncologist.2018-0149

Ejemplares similares